NCT01294605 - Immunogenicity and Reactogenicity Study of BoostrixTM (dTpa) and Boostrix-IPV (dTpa-IPV) | Biotech Hunter

Enrollment

460

Participants

Timeline

Start Date

April 30, 2003

Primary Completion Date

September 30, 2004

Study Completion Date

September 30, 2004

Conditions

Acellular PertussisTetanusDiphtheria

Interventions

BIOLOGICAL

Boostrix™ (dTpa)

Intramuscular, 3 doses

BIOLOGICAL

GSK Biologicals' reduced-antigen-content combined diphtheria, tetanus, acellular pertussis and inactivated polio vaccine (dTpa-IPV; BoostrixTM)

Intramuscular, single dose

BIOLOGICAL

Ditanrix™ Adult, TedivaxTM (Td)

Intramuscular, 2 doses

BIOLOGICAL

Ditanrix™ Adult, TedivaxTM (Td)

Intramuscular, 3 doses

Trial Locations (13)

2610

GSK Investigational Site, Wilrijk

3000

GSK Investigational Site, Leuven

8000

GSK Investigational Site, Bruges

8025

GSK Investigational Site, Barcelona

28040

GSK Investigational Site, Madrid

28500

GSK Investigational Site, Vic

46600

GSK Investigational Site, Alzira

3015 GE

GSK Investigational Site, Rotterdam

3584 CJ

GSK Investigational Site, Utrecht

08035

GSK Investigational Site, Barcelona

08036

GSK Investigational Site, Barcelona

Unknown

GSK Investigational Site, Centelles

08100

GSK Investigational Site, Mollet del Vallès